Thrombosis and atherosclerosis

Current Opinion in Lipidology

Volumn 8, Issue 5, 1997, Pages 320-328

  Holvoet, Paul ^a   Collen, Désiré ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRIN; FIBRINOGEN; FIBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; METALLOPROTEINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VITRONECTIN; VON WILLEBRAND FACTOR;

ANTICOAGULATION; ATHEROSCLEROSIS; BLOOD LEVEL; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FIBRIN POLYMERIZATION; FIBRINOLYSIS; FOAM CELL; GENETIC POLYMORPHISM; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; LEUKOCYTE ADHERENCE; MACROPHAGE; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SHEAR STRESS; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOSIS;

EID: 0030730606     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199710000-00012     Document Type: Review

References (89)

1. Zimmerman GA, McIntyre TM, Prescott SM: Adhesion and signaling in vascular cell-cell interactions. J Clin Invest 1996, 98:1699-1702.
2. Ben-Baruh A, Michiel DF, Oppenheim JJ: Signals and receptors involved in recruitment of inflammatory cells. J Biol Cell 1995, 270:11703-11706
3. Takahashi M, Kitagawa S, Masuyama JI, Ikeda U, Kasahara T, Takahashi Yl, Furukawa Y, Kano S, Shimada K. Human monocyte-endothelial cell interaction induces synthesis of granulocyte-macrophage colony-stimulating factor. Circulation 1996, 93:1185-1193.
4. Johnson Tidey RR, McGregor JL, Taylor PR, Poston RN: Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1. Am J Pathol 1994, 144:952-961.
5. Poston RN, Johnson Tidey RR: Localized adhesion of monocytes to human atherosclerotic plaques demonstrated in vitro: implications for atherogenesis. Am J Pathol 1996, 149:73-80.
6. Murohara T, Scalia R, Lefer AM: Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Circ Res 1996, 78:780-789.
7. Mehta A, Yang B, Khan S, Hendricks JB, Stephen C, Mehta JL: Oxidized low-density lipoproteins facilitate leukocyte adhesion to aortic intima without affecting endothelium-dependent relaxation. Role of P-selectin. Arterioscler Thromb Vasc Biol 1995, 15:2076-2083.
8. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993, 92:1866-1874.
9. Wenzel K, Ernst M, Ronde K, Baumann G, Speer A: DNA polymorphisms in adhesion molecule genes - a new risk factor for early atherosclerosis. Hum Genet 996, 97:15-20. Suggests that polymorphism in adhesion molecule genes may be markers for patients at increased risk for atherosclerotic cardiovascular disease.
10. Haught WH, Mansour M, Rothlein R, Kishimoto TK, Mainolfi EA, Hendricks JB, Hendricks C, Mehta JL: Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am Heart J 1996, 132:1-8.
11. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, Tall A: Interleukin-8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 1996, 271:8837-8842. Demonstrates a link between foam cell generation in the subendothelial layer and induction of monocyte endothelium interactions.
12. Taub DD, Longo DL, Murphy WJ: Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. Blood 1996, 87:1423-1431.
13. Wang X, Yue TL, Ohlstein EH, Sung CP, Feuerstein GZ: Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J Biol Chem 1996, 271:24286-24293.
14. Menschikowski M, Kasper M, Lattke P, Schiering A, Schiefer S, Stockinger H, Jaross W: Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 1995, 118:173-181.
15. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT: Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995, 15:1145-1151.
16. Bjorkerud S, Bjorkerud B: Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 1996, 149:367-380.
17. Fleming I, Bauersachs J, Busse R: Paracrine functions of the coronary vascular endothelium. Mol Cell Biochem 1996, 157:137-145.
18. Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM: Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995, 15:1652-1659.
19. Tsao PS, Lewis NP, Alpert S, Cooke JP: Exposure to shear stress alters endothelial adhesiveness. Role of nitric oxide. Circulation 1995, 92:3513-3519.
20. Eizawa H, Yui Y, Inoue R, Kosuga K, Hattori R, Aoyama T, Sasayama S: Lysophosphatidylcholine inhibits endothelium-dependent hyperpolarization and N omega-nitro-L-arginineiindomethacin-resistant endothelium-dependent relaxation in the porcine coronary artery. Circulation 1995, 92:3520-3526.
21. Minuz P, Lechi C, Gaino S, Bonapace S, Fontana L, Garbin U, Paluani F, Cominacini L, Zatti M, Lechi A: Oxidized LDL and reduction of the antiaggregating activity of nitric oxide derived from endothelial cells. Thromb Haemost 1995, 74:1175-1179.
22. Wu KK, Thiagarajan P: Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996, 47:315-331.
23. Watkins MT, al-Badawi H, Cardenas R, Dubois E, Larson DM: Endogenous reactive oxygen metabolites mediate sublethal endothelial cell dysfunction during reoxygenation. J Vasc Surg 1996, 23:95-103.
24. Myers SI, Tumage RH, Kadesky KM, Seelig AR, Bartula L: Endotoxic shock after long-term resuscitation of hemorrhageireperfusion Injury decreased splanchnic blood flow and eicosanoid release. Ann Surg 1996, 224:213-218.
25. Yamagishi S, Yamamoto Y, Harada S, Hsu CC, Yamamoto H: Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett 1996, 384:103-106.
26. Farhat MY, Lavigne MC, Ramwell PW: The vascular protective effects of estrogen. FASEB J 1996, 10:615-624.
27. Ginon I, Talussot C, Ponsin G, Ciavatti M: Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high-density lipoproteins in experimental diabetes. Acta Diabetol 1995, 32:170-175.
28. Umeda F, Ono Y, Masakado M, Sekiguchi N, Yamauchi T, Hashimoto T, Nawata H: Prostacyclin-stimulating factor, novel protein, and diabetic angiopathy. Diabetes 1996, 45:S111-S113.
29. Farber HW, Barnett HF: Differences in prostaglandin metabolism in cultured aortic and pulmonary arterial endothelial cells exposed to acute and chronic hypoxia. Circ Res 1991, 68:1446-1457.
30. Lynch SM, Morrow JD, Roberts LJn. Frei B: Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest 1994, 93:998-1004.
31. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJd: Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids Proc Natl Acad Sci USA 1992, 89:10721-10725.
32. Morrow JD, Roberts LJ: The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996, 51:1-9.
33. Laskey RE, Mathews WR: Nitric oxide inhibits peroxynitrite-induced production of hydroxyeicosatetraenoic acids and F2-isoprostanes in phosphatidylcholine liposomes. Arch Biochem Biophys 1996, 330:193-198.
34. Pratico D, FitzGerald GA: Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem 1996, 271:8919-8924.
35. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D: Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995, 95:2611-2619.
36. Lip GY, Blann AD: von Willebrand factor and its relevance to cardiovascular disorders. Br Heart J 1995, 74:580-583.
37. Sixma JJ, Ijsseldijk MJ, Hindriks G, van Zanten GH, Gorecki M, Panet A, Garfinkel LI, de Groot PG: Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. Arterioscler Thromb Vasc Biol 1996, 16:64-71.
38. Cortellaro M, Baldassarre D, Cofrancesco E, Tremoli E, Colombo A, Boschetti C, Paoletti R: Relation between hemostatic variables and increase of common carotid intima-media thickness in patients with peripheral arterial disease. Stroke 1996, 27:450-454.
39. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D: Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996, 76:663-669.
40. Godyna S, Diaz-Ricart M, Argraves WS: Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen. Blood 1996, 88:2569-2577 Illustrates the role of interaction between the extracellular matrix protein tibulin-1 and the plasma protein fibrinogen for platelet adhesion after eidothelial denudation.
41. Dentan C, Lesnik P, Chapman MJ, Ninio E: Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the inflammatory reaction in atherogenesis. Eur J Biochem 1996, 236:48-55.
42. Schini-Kerth VB, Fissithaler B, Van Obberghen-Schilling E, Busse R: Serotonin stimulates the expression of thrombin receptors in cultured vascular smooth muscle cells. Role of protein kinase C and protein tyrosine kinases. Circulation 1996, 93:2170-2177.
43. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E: PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995, 15:1764-1773.
44. Scalia R, Murohara T, Delyani JA, Nossuli TO, Lefer AM: Myocardial protection by N, N, N-trimethylsphingosine in ischemia reperfusion injury is mediated by inhibition of P-selectin. J Leukoc Biol 1996, 59:317-324.
45. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A: Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996, 93:229-237.
46. Diacovo TG, Puri KD, Warnock RA, Springer TA, von Andrian UH: Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996, 273:252-255. Shows that activated platelet P-selectin, independent of endothelial L-selectin, may mediate leukocyte telhering.
47. Lehr HA, Olofsson AM, Carew TE, Vajkoczy P, von Andrian UH, Hubner C, Berndt MC, Steinberg D, Messmer K, Arfors KE: P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab Invest 1994,71:380-386.
48. Kuijper PH, Gallardo Torres HI, van der Linden JA, Lammers JW, Sixma JJ, Koenderman L, Zwaginga JJ: Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood 1996, 87:3271-3281. Shows that platelet-dependent haemostasis at the subendothelial matrix is a powerful means for neutrophil arterial wall interactions at shear stresses that normally do not allow neutrophil adhesion to endothelium.
49. Chen LY, Mehta JL: Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J Cardiovasc Pharmacol 1996, 27:154-158.
50. Chen LY, Mehta JL: Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J Pharmacol Exp Ther 1996, 276:253-257.
51. Chen LY, Mehta P, Mehta JL: Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation 1996, 93:1740-1746. Illustrates the association between oxidation of LDL and platelet activation.
52. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, Zimmerman GA: Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996, 97:1525-1534. Shows that activated platelets may induce leukocyte adhesion and extravasation by inducing secretion of interleukin-8 and monocyte chemoattractant protein-1.
53. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A: Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996, 75:389-392.
54. Lewis JC, Bennett Cain AL, DeMars CS, Doellgast GJ, Grant KW, Jones NL, Gupta M: Procoagulant activity after exposure of monocyte-derived macrophages to minimally oxidized low density lipoprotein. Co-localization of tissue factor antigen and nascent fibrin fibers at the cell surface. Am J Pathol 1995, 147:1029-1040.
55. Abumiya T, Yamaguchi T, Terasaki T, Kokawa T, Kario K, Kato H: Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb Haemost 1995, 74:1050-1054.
56. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ: Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995, 92:3041-3050.
57. Lesnik P, Dentan C, Vonica A, Moreau M, Chapman MJ: Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell-and copper-mediated oxidation. Arterioscler Thromb Vasc Biol 1995, 15:1121-1130.
58. •].
59. •] show the association between factor X activation, platelet-derived growth factor release and LDL receptor-related protein in smooth muscle cells and thus between coagulation and smooth muscle foam cell generation.
60. Schini-Kerth VB, Fissithaler B, Andersen TT, Fenton JWn, Vanhoutte PM, Busse R: Thrombin prevents the expression of inducible nitric oxide synthase in vascular smooth muscle cells by a proteolytically activated thrombin receptor. Thromb Haemost 1995, 74:980-986
61. Wenzel UO, Fouqueray B, Grandaliano G, Kim YS, Karamitsos C, Valente AJ, Abboud HE: Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells. Circ Res 1995, 77:503-509.
62. Fabunni RP, Baker AH, Murray EJ, Booth RF, Newby AC: Divergent regulation by growth factors and cytokines of 95 KDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem J 1996, 315:335-342
63. Weis JR, Pitas RE, Wilson BD, Rodgers GM: Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB J 1991, 5:2459-2465.
64. Delafontaine P, Anwar A, Lou H, Ku L: G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rataortic smooth muscle cells. J Clin Invest 1996, 97:139-145. Supports the concept of cross talk between G-proteins and tyrosine kinase receptors in the thrombin-mediated activation o1 smooth muscle cells.
65. Shirk RA, Church FC, Wagner WD: Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II. Arterioscler Thromb Vasc Bioll 1996, 16:1138-1146.
66. Sarembock IJ, Gertz SD, Thome LM, McCoy KW, Ragosta M, Powers ER, Maraganore JM, Gimple LW: Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. J Vasc Res 1996, 33:308-314.
67. Ragosta M, Barry WL, Gimple LW, Gertz SD, McCoy KW, Stouffer GA, McNamara CA, Powers ER, Owens GK, Sarembock IJ: Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits. Circulation 1996, 93:1194-1200.
68. Harpel PC, Zhang X, Borth W: Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr 1996, 126:12853-12893.
69. Matthias D, Becker CH, Riezler R, Kindling PH: Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 1996, 122:201-216.
70. Kannel WB, Wolf PA, Castelli WP, D'Agostini RB: Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987, 258:1185-1186.
71. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D: Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995, 92:31-38.
72. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK: Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995, 91:284-290.
73. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Study Group. N Engl J Med 1995, 332:635-641.
74. Zitoun D, Bara L, Basdevant A, Samama MM: Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler Thromb Vasc Biol 1996, 16:77-81. Shows that hypercoagulability in combination with hypofibrinolysis may explain the prothrombotic tendency in hyperlipidaemic patients.
75. Sironi L, Mussoni L, Prati L, Baldassarre D, Camera M, Banfi C, Tremoli E: Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996, 16:89-96.
76. Brown SL, Sobel BE, Fujii S: Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and flbrinolysis [see comments]. Circulation 1995, 92:767-772.
77. Holvoet P, Collen D: Lipid lowering and enhancement of fibrinolysis with niacin editorial; comment. Circulation 1995, 92:698-699.
78. Li XN, Koons JC, Benza RL, Parks JM, Varma VK, Bradley WA, Gianturco SH, Taylor KB, Grammer JR, Tabengwa EM, Booyse FM: Hypertriglyceridemic VLDL decreases plasminogen binding to endothelial cells and surface-localized fibrinolysis. Biochemistry 1996, 35:6080-6088.
79. Loskutoff DJ, van Aken BE, Seiffert D: Abnormalities in the fibrinolytic system of the vascular wall associated with atherosclerosis. Ann NY Acad Sci 1995, 748:177-184.
80. Robbie LA, Booth NA, Brown AJ, Bennett B: Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996, 16:539-545.
81. Shireman PK, McCarthy WJ, Pearce WH, Patterson BK, Shively VP, Cipollone M, Tamarina N, Verrusio EN, Kwaan HC: Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta. J Vasc Surg 1996, 23:810-817.
82. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J: Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995, 15:893-902.
83. Stefansson S, Lawrence DA: The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta3 binding to vitronectin [see comments]. Nature 1996, 383:441-443. Shows that plasminogen activators are critical for smooth muscle cell migration that may be blocked by PAI-1.
84. Stefansson S, Lawrence DA, Argraves WS: Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 1996, 271:8215-8220. Shows that PAI-1 downregulates the growth factor-like activities of thrombin by stimulating thrombin clearance.
85. Waltz DA, Sailor LZ, Chapman HA: Cytokines Induce urokinase-dependent adhesion of human myeloid cells. A regulatory role of plasminogen activator inhibitors. J Clin Invest 1993, 91:1541-1552.
86. Montrucchio G, Lupia E, De Martino A, Silvestro L, Savu SR, Cacace G, De Filippi PG, Emanuelli G, Camussi G: Plasmin promotes an endothelium-dependent adhesion of neutrophils. Involvement of platelet activating factor and P-selectin. Circulation 1996, 93:2152-2160.
87. Schneiderman J, Bordin GM, Engelberg I, Adar R, Seiffert D, Thinnes J, Bernstein EF, Dilley RB, Loskutoff DJ: Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest 1995, 96:639-645.
88. Hajjar KA, Nachmann RL: The role of lipoprotein (a) in atherogenesis and thrombosis. Annu Rev Med 1996, 47:423-442.
89. Grainger DJ, Metcalfe JC: Transforming growth factor-beta: the key to understanding lipoprotein (a)? Curr Opin Lipidol 1995, 6:81-85.